The experimental strategy included both an additional sedative and its antagonist.
The randomized partial-hepatectomy trial compared remimazolam–propofol with flumazenil reversal against propofol alone. Command following, a bispectral-index milestone and tube removal occurred sooner with the combined strategy. Selected pain and recovery-unit measures also differed.
These findings do not isolate spontaneous remimazolam recovery. The authors acknowledged a small sample, selected liver-function categories and short follow-up. Immediate emergence measures cannot establish long-term hepatic protection or sustained cognitive recovery.
Name all components when describing the benefit. Calling this simply remimazolam versus propofol erases the reversal intervention and continued propofol exposure. For a forensic chronology, follow the infusion changes, antagonist timing and subsequent responsiveness; a group average cannot reconstruct an individual concentration or prove that later somnolence had a single cause.
Source: PMC12335263, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Aminophylline Emergence Results Do Not Establish Specific Midazolam Reversal.